Lilly Asia Ventures
Lilly Asian Ventures is an investment firm that invests in promising life science companies.
Business Model:
Revenue: $0
Employees: 0-0
Rankings
Industries / Tags:
Detailed Lilly Asia Ventures Information
Geographic Data
Address: No.168 Hubin Road
City: Huangpu
State: shanghai municipality
Zip: 200021
Country: CN
Financial Info
Stage:
Raised Last:
$0
Raised Total:$2B
Social
Linkedin
Crunchbase
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
Lilly Asian Ventures makes venture capital investments in Asia for Eli Lilly and Company, a global innovation-driven pharmaceutical company. Lilly Asian Ventures invests in promising life science companies with strong management teams and innovative technology and/or business models. Their initial focus will be primarily on opportunities in China, although they will consider investment opportunities elsewhere in east and south Asia.
Contact Phone:
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 11/2012 | Innovent Biologics | Series B | 30M |
| 9/2022 | Neukio Biotherapeutics | Series A | 50M |
| 1/2021 | Targeting One | Series B | 23.2M |
| 1/2017 | ClinChoice昆翎 | Series C | - |
| 12/2019 | Geneseeq | Series D | 114.5M |
| 10/2019 | ClinChoice昆翎 | Series D | 62M |
| 8/2017 | Hangzhou Just Biotherapeutics (Just China) | Series B | 59.6M |
| 11/2021 | Singleron Biotechnologies | Series B | 0 |
| 7/2016 | Hangzhou Just Biotherapeutics (Just China) | Series A | 14M |
| 11/2021 | Cornerstone Robotics | Series B | 0 |
| 12/2022 | Ronovo Surgical | Series B | - |
| 2/2021 | Regor Therapeutics | Series B | 0 |
| 7/2014 | IMPACT Therapeutics | Series A | - |
| 3/2018 | Singlera Genomics | Series A | 0 |
| 9/2020 | Sonoma Pharmaceuticals | Post-IPO Equity | 70M |
| 3/2019 | InventisBio | Series C | 70M |
| 11/2014 | Hitales | Angel Round | 3M |
| 5/2019 | Inhibrx | Private Placement | 40M |
| 1/2016 | NextCure | Series A | 67M |
| 3/2020 | Rongchang Pharmaceutical | Series A | - |
| 1/2021 | Terns Pharmaceuticals | Series C | 87M |
| 5/2017 | Turning Point Therapeutics | Series C | 45M |
| 9/2020 | Sonoma BioTherapeutics | Series A | 0 |
| 10/2018 | Terns Pharmaceuticals | Series B | 80M |
| 5/2021 | NiKang Therapeutics | Series C | 200M |
| 1/2018 | Tmunity Therapeutics | Series A | 0 |
| 9/2019 | Passage Bio | Series B | 110M |
| 11/2020 | CARsgen Therapeutics | Series C | 0 |
| 3/2021 | Qihan Biotech | Series A | 67M |
| 2/2019 | Gracell Biotechnologies | Series B | 85M |
| 12/2020 | SciNeuro | Series A | 100M |
| 8/2021 | Ionova Life Science | Private Equity Round | 100M |
| 10/2019 | Ionova Life Science | Series A | 17.8M |
| 6/2022 | ProfoundBio | Series A | 0 |
| 4/2021 | Nucleix | Venture Round | 55M |
| 3/2021 | NovoCodex | Series A | 61.5M |
| 11/2021 | Novlead Biotech | Series B | 18.8M |
| 10/2021 | ShouTi | Series B | 0 |
| 10/2021 | OriGynMED | Series B | - |
| 3/2021 | FutureGen | Series B | 46.1M |
| 1/2014 | ClinChoice昆翎 | Series B | - |
| 9/2016 | WT Microtech Medical | Series A | - |
| 8/2021 | Pulnovo Medical | Venture Round | 15.5M |
| 2/2016 | Microtech Medical | Series A | 24.3M |
| 3/2021 | Sichuan Kelun Pharmaceutical | Funding Round | - |
| 12/2020 | WT Microtech Medical | Series D | 0 |
| 6/2018 | Hangzhou Just Biotherapeutics (Just China) | Series B | 0 |
| 8/2021 | LYNK Pharmaceuticals | Series B | 0 |
| 8/2021 | MediTrust Health | Series C | 0 |
| 1/2020 | Ronovo Surgical | Seed Round | - |
| 4/2021 | Ronovo Surgical | Series A | - |
| 4/2016 | ACEA BIO | Series E | 6M |
| 5/2014 | Crown Bioscience | Series D | 26.6M |
| 8/2021 | Zentera Therapeutics | Series B | 75M |
| 8/2020 | Connect Biopharmaceuticals | Series C | 115M |
| 10/2020 | Gracell Biotechnologies | Series C | 0 |
| 1/2019 | Transcenta | Venture Round | - |
| 9/2021 | XellSmart | Seed Round | 11.9M |
| 10/2021 | WT Microtech Medical | Series E | 153M |
| 8/2021 | Scivita Medical Technology | Series B | 0 |
| 1/2020 | Alebund Pharmaceuticals | Series A | - |
| 4/2022 | Rona Therapeutics | Series A | 0 |
| 2/2016 | IMPACT Therapeutics | Series B | 10M |
| 5/2021 | Rgenta Therapeutics | Seed Round | 18M |
| 10/2019 | dMed | Series B | 50M |
| 3/2020 | Remegen | Private Equity Round | 0 |
| 12/2020 | Virtue Diagnostics | Series A | 30M |
| 10/2019 | Ansun BioPharma | Series B | 100M |
| 8/2018 | EdiGene | Series A | 14.5M |
| 2/2017 | Abbisko Therapeutics | Series A | 28M |
| 10/2021 | Hopstem | Series B | 40M |
| 10/2015 | MabSpace Biosciences | Series A | 15M |
| 8/2018 | Magnolia NeuroSciences | Series A | 0 |
| 1/2016 | Tmunity Therapeutics | Venture Round | 10M |
| 1/2018 | Sansure Biotech | Corporate Round | 77M |
| 11/2015 | ACEA BIO | Venture Round | 30M |
| 5/2018 | MabSpace Biosciences | Series B | 40M |
| 9/2019 | Insilico Medicine | Series B | 37M |
| 2/2019 | NuVera Medical | Series B | 15M |
| 11/2021 | Positive Sequence Biology | Series A | 0 |
| 9/2020 | InventisBio | Series D | 0 |
| 1/2019 | Geneception | Series A | - |
| 1/2022 | Virtue Diagnostics | Series B | 0 |
| 3/2019 | Abbisko Therapeutics | Series B | 42M |
| 1/2020 | Transcenta | Series B | 0 |
| 6/2018 | Metacrine | Series C | 65M |
| 9/2016 | ReadCoor | Series A | 23M |
| 2/2019 | Burning Rock Biotech | Series C | 125.5M |
| 9/2021 | ADARx Pharmaceuticals | Series B | 75M |
| 5/2021 | Alebund Pharmaceuticals | Series B | 0 |
| 5/2018 | Ansun BioPharma | Series A | 85M |
| 11/2022 | Rgenta Therapeutics | Series A | 0 |
| 8/2021 | Sonoma BioTherapeutics | Series B | 0 |
| 7/2021 | Neukio Biotherapeutics | Angel Round | 40M |
| 11/2020 | Eluminex Biosciences | Series A | 50M |
| 2/2019 | Passage Bio | Series A | 115.5M |
| 9/2017 | Gritstone Bio | Series B | 93M |
| 3/2018 | Tempest Therapeutics | Series B | 70M |
| 12/2022 | LavaMed | Series A | 0 |
| 5/2021 | Elpiscience Biopharmaceuticals | Series C | 0 |
| 4/2023 | Alebund Pharmaceuticals | Series C | 0 |
| 8/2021 | Abogen Biosciences | Series C | 0 |
| 3/2022 | IMPACT Therapeutics | Series D | - |
| 4/2018 | Tmunity Therapeutics | Series A | 0 |
| 4/2021 | Scivita Medical Technology | Series A | 0 |
| 9/2020 | NiKang Therapeutics | Series B | 50M |
| 9/2020 | Singleron Biotechnologies | Series A | 30M |
| 5/2021 | Duality Biologics | Series B | 0 |
| 9/2015 | Hangzhou Just Biotherapeutics (Just China) | Series A | 15M |
| 5/2017 | InventisBio | Series B | 19M |
| 6/2021 | ArriVent Biopharma | Series A | 81M |
| 5/2018 | Avedro | Series F | 0 |
| 1/2021 | Abbisko Therapeutics | Series D | 123M |
| 8/2020 | Dizal Pharma | Venture Round | 100M |
| 12/2018 | Elpiscience Biopharmaceuticals | Series A | 35M |
| 4/2018 | Innovent Biologics | Series E | 150M |
| 10/2021 | CinCor Pharma | Series B | 0 |
| 7/2016 | Just - Evotec Biologics | Series A | 14M |
| 11/2022 | Pulnovo Medical | Venture Round | - |
| 12/2021 | ImmuneOnco Biopharma | Venture Round | 100M |
| 2/2022 | GluBio Therapeutics | Series A | 0 |
| 8/2016 | Singlera Genomics | Series A | 20M |
| 11/2015 | CanSinoBIO | Series C | 30M |
| 2/2022 | ArriVent Biopharma | Series A | 69M |
| 11/2018 | Harpoon Therapeutics | Series C | 70M |
| 9/2016 | Fortis Therapeutics | Series A | 18M |
| 3/2021 | Fortis Therapeutics | Series A | 0 |
| 7/2022 | ClinChoice昆翎 | Series E | 0 |
| 4/2020 | Legend Biotech | Series A | 0 |
| 6/2021 | Synthekine | Series B | 0 |
| 4/2017 | NuVera Medical | Series A | 11M |
| 1/2022 | ImmuneOnco Biopharma | Series C | 100M |
| 1/2015 | Innovent Biologics | Series C | 115M |
| 10/2021 | Structure Therapeutics | Series B | 0 |
| 9/2021 | Alebund Pharmaceuticals | Series B | 0 |
| 8/2018 | IMPACT Therapeutics | Series C | 30M |
| 3/2021 | Kelun Biotech | Series A | 78.5M |
| 12/2020 | IMPACT Therapeutics | Series C | 0 |
| 9/2019 | EdiGene | Series A | 11.5M |
| 2/2017 | Jacobio Pharmaceuticals | Series B | - |
| 9/2021 | FORQALY | Series B | - |
| 6/2023 | Novlead Biotech | Series B | - |
| 6/2023 | Langlai Technology | Series A | 0 |
| 4/2023 | Bioyond Tech | Series A | 0 |
| 1/2023 | Yinghe Brain Science | Angel Round | 0 |
| 1/2023 | ADARx Pharmaceuticals | Series B | 0 |
| 11/2018 | NextCure | Series B | 93M |
| 10/2018 | Turning Point Therapeutics | Equity | 80M |
| 12/2015 | 360 Health | Series A | 15.6M |
| 3/2020 | Abbisko Therapeutics | Series C | 70M |
| 4/2018 | Terns Pharmaceuticals | Series A | 30M |
| 1/2018 | Peijia Medical | Series B | - |
| 3/2016 | Mailing Yiliao | Series A | 1.5M |
| 12/2022 | ArriVent Biopharma | Series B | 0 |
| 7/2020 | New Horizon Health | Series E | 30M |
| 6/2015 | Veritas Genetics | Series A | 12M |
| 1/2016 | InventisBio | Series A | 11M |
| 11/2019 | Peijia Medical | Series C | 100M |
| 5/2010 | Betta Pharmaceuticals | Series A | 499.7M |
| 2/2019 | EdiGene | Series A | 10M |
| 4/2017 | Elpiscience Biopharmaceuticals | Series A | 20M |
| 4/2017 | CanSinoBIO | Series E | 0 |
| 10/2016 | Veritas Genetics | Series B | 0 |
| 12/2020 | dMed | Series C | 100M |
| 7/2021 | ProfoundBio | Series A | 0 |
| 5/2016 | 360 Haoyao | Series A | 15.2M |
| 8/2021 | MediTrust Health | Series C | 308.3M |
| 4/2021 | EdiGene | Series B | 61.6M |
| 9/2013 | CanSinoBIO | Venture Round | 10M |
| 2/2022 | Pilot Biotechnology | Series C | 0 |
| 1/2018 | Geneception | Seed Round | - |
| 6/2021 | Insilico Medicine | Series C | 0 |
| 7/2018 | Alector | Series E | 133M |
| 10/2020 | EdiGene | Series B | 0 |
| 12/2019 | Elpiscience Biopharmaceuticals | Series B | 0 |
| 10/2020 | ImmuneOnco Biopharma | Series B | 25M |
| 8/2008 | HD Biosciences | Series A | - |
| 11/2021 | Tripod Preclinical Research Laboratories | Venture Round | 0 |
| 9/2018 | KSQ Therapeutics | Series C | 80M |
| 9/2019 | Insilico Medicine | Series B | 37M |
| 9/2015 | Just - Evotec Biologics | Series A | 15M |
| 6/2023 | Novlead Biotech | Series B | - |
| 6/2023 | Langlai Technology | Series A | 0 |
| 4/2023 | Alebund Pharmaceuticals | Series C | 0 |
| 4/2023 | Bioyond Tech | Series A | 0 |
| 1/2023 | Yinghe Brain Science | Angel Round | 0 |
| 1/2023 | ADARx Pharmaceuticals | Series B | 0 |
| 12/2022 | ArriVent Biopharma | Series B | 0 |
| 12/2022 | Ronovo Surgical | Series B | - |
| 12/2022 | LavaMed | Series A | 0 |
| 11/2022 | Rgenta Therapeutics | Series A | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
